1	Exposure to valsartan products containing nitrosamine impurities in the US, Canada, and
2	Denmark.
3	Short title: Exposure to valsartan products with nitrosamine impurities
4	Efe Eworuke, PhD, ¹ Mayura U. Shinde, ² Laura Hou, ² J. Michael Paterson, MSc ³ Peter Bjødstrup
5	Jensen, PhD, ⁴ Judith C. Maro, PhD, ² Ashish Rai, PhD, MSPH, MBBS2 ² Anton Pottegård, PhD ⁴
6	Daniel Scarnecchia, MPIA ² Yuanling Liang, PhD ¹ , Deborah Johnson, PhD, ¹ Robert W. Platt,
7	PhD ³ , Hana Lee, PhD ¹ Marie C. Bradley, PhD, MPharm, MSc.PH ¹
8	Author Affiliations:
9	1. Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring,
10	MD, USA
11	2. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
12	Health Care Institute, Boston, MA, USA
13	3. Canadian Network for Observational Drug Effect Studies (CNODES), Montréal, QC, CA
14	4. University of Southern Denmark, Odense, DK
15	Corresponding author: Marie C. Bradley
16	Division of Epidemiology II, Center for Drug Evaluation and Research, U.S. Food and Drug
17	Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993
18	Telephone: 240-402-9985
19	Fax: 301-796-9850
20	Email: marie.bradley@fda.hhs.gov
21	Abstract word count: 341

- 22 Manuscript word count: 2267
- 23 Disclaimer: The views expressed in this publication are those of the authors and should not be
- 24 construed to represent the official policy or views of the US Food and Drug Administration or
- 25 Health Canada.

26 ABSTRACT

Background: Following the mass recall of valsartan products with nitrosamine impurities in July
2018, the number of patients exposed to these valsartan products, the duration of exposure, and
the potential for cancer remains unknown. Therefore, we assessed the extent and duration of use
of valsartan products with a nitrosamine impurity in the US, Canada, and Denmark.

31 Methods: We conducted a retrospective cohort study using administrative healthcare data from

32 the US FDA Sentinel System, four Canadian provinces that contribute to the Canadian Network

33 for Observational Drug Effect Studies (CNODES), and the Danish National Prescription

Registry. Patients, 18 years and older between May 2012 and December 2020 with a valsartan

35 dispensing were identified in each database. Patients were followed from the date of valsartan

36 dispensing until discontinuation. We defined four valsartan exposure categories based on

37 nitrosamine impurity status; recalled generic products with confirmed NDMA/NDEA levels

38 (recalled-tested); recalled generic products that were not tested (recalled); non-recalled generic

39 and non-recalled branded products. In Denmark, recalled-tested category was not included due to

40 absence of testing data. The proportion and duration of use of valsartan episodes stratified by

41 nitrosamine-impurity status.

42 Results: We identified 3.3 and 2.8 million (US) and 51.3 and 229 thousand (Canada) recalled-

43 tested and recalled valsartan exposures. In Denmark, where valsartan exposure was generally

44 low, there were 10,747 recalled exposures. Immediately after the recall notices were issued, there

45 was increased rates of switching to a non-valsartan ARB. The mean duration of use of the

46 recalled-tested products was $167(\pm 223.1)$ and $146(\pm 255.8)$ days in the US and Canada

47 respectively. For the recalled products, mean cumulative duration of use was $178(\pm 249.6)$,

48 $269(\pm 397.3)$ and $166(\pm 251.0)$ days in the US, Canada, and Denmark, respectively.

- 49 Conclusion: In this cohort study, despite widespread use of recalled generic valsartan between
- 50 2012 and 2018, the duration of use was relatively short and likely did not pose an elevated risk of
- 51 nitrosamine-induced cancer. However, since products with nitrosamine impurity could have been
- 52 on the market over a six-year period, patients potentially exposed to these products for longer
- 53 duration could have a different risk of cancer.

55 **INTRODUCTION**

56 The mass recall of valsartan products with nitrosamine impurities in July 2018 prompted a series 57 of investigations into the etiology and level of nitrosamine impurities, and the potential for 58 cancer risk. Regulatory agencies quickly learned that the presence of N-nitrosodimethylamine 59 (NDMA) and N-nitroso-diethylamine (NDEA) impurities in some valsartan products occurred as far back as 2012^{1-5} due to a change in manufacturing processes. Our previous study⁶ investigated 60 61 trends in valsartan and other ARB use and found that the first recall notice for valsartan resulted 62 in substantial decline in use due to increased switching to other ARBs. However, the extent of 63 exposure to valsartan products with nitrosamine impurities before the recall, and the associated 64 potential cancer risk remains unknown. In October 2018, regulatory agencies published test results showing NDMA levels in recalled valsartan products exceeded safe levels.^{6,7} The results 65 66 were subsequently updated in February 2019 with the NDEA levels. For reference, consuming up to 0.096 micrograms (mcg) of NDMA or 0.0265 mcg of NDEA per day is considered 67 68 reasonably safe for human ingestion based on lifetime exposure. The highest NDMA levels were 69 between 14 and 20 mcg, while the highest NDEA levels were between 1.1 and 1.3 mcg. Since 70 cancer risk is dependent on both dose and years of exposure, it was determined that if 8,000 71 patients took the maximum recommended daily dose (320mg daily) of valsartan containing 72 NDMA at levels of 96 ng/day (0.096 mcg) and 18,000 people took the highest dose of valsartan 73 containing NDEA at levels of 26.5 ng/day (or 0.0265 mcg/day) for four years, there may be only one additional cancer case.⁷ This study examined the extent and duration of use of valsartan 74 75 products with nitrosamine impurities and estimated the potential for cancer based on the 76 observed duration of use of these products in the US, Canada, and Denmark.

78 METHODS

79 A retrospective cohort study was conducted between January 1, 2012, through December 31, 80 2020, using data from six data partners that contribute data to the US FDA Sentinel System, data 81 from four Canadian provinces that contribute to the Canadian Network for Observational Drug 82 Effect Studies (CNODES), and the Danish National Prescription Registry. The FDA's Sentinel 83 system includes data on medical encounters (inpatient and outpatient diagnoses and procedures) 84 and outpatient pharmacy claims data (retail and mail order filled prescriptions) accrued during 85 health plan enrollment periods. These data are routinely quality-assured and transformed into the Sentinel Common Data Model to facilitate queries.¹² Additional descriptions of data sources are 86 87 provided in Supplement A.

88 We included patients aged 18 years and older with at least one valsartan dispensing during the 89 study period, between January 2012 to December 2020 for US and Canada and January 2012 to 90 May 2020 for Denmark. Four valsartan exposure categories were defined based on valsartan 91 impurity status; recalled products with a laboratory test result confirming the presence of 92 NDMA/NDEA based on FDA and Health Canada analyses (recalled-tested); recalled products 93 that were not tested (recalled); non-recalled generic and non-recalled branded valsartan-94 containing products (Diovan, Entresto, Exforge and Sandoz-Valsartan). In Denmark, we did not 95 have access to NDMA/NDEA testing data, hence valsartan products were categorized into 96 recalled, non-recalled generic and non-recalled branded categories. The algorithms for exposure 97 definitions are presented in supplement B. Valsartan exposure episodes were created by 98 summing the number of days dispensed with a gap of 30 days or less for the respective exposure 99 category. Patients were followed until they discontinued the product, switched to another 100 valsartan exposure category or a different angiotensin receptor blocker (ARB), disenrollment,

101	death, or study end date. We calculated the proportion of valsartan episodes as the number of
102	valsartan episodes in each exposure category divided by the total valsartan episodes each quarter
103	per year. We also calculated the rate of switching, defined as the number of valsartan episodes
104	for each exposure category that ended in a switch, divided by the total valsartan episodes each
105	quarter per year. Lastly, we estimated the length of episode duration by calculating mean,
106	median and quartiles (lowest and highest median, 25 th and 75 th percentile recorded across the
107	data partners) between May 2012 and December 2018 (period when we assumed valsartan
108	products with NDMA/NDEA impurity were on the market) for each recall category. All source
109	data were transformed into the Sentinel common data model ¹¹ , and analyzed using Sentinel's
110	Query Request Program v10.1.1 with custom coding, allowing for the deployment of a common
111	analytical program in all countries.
112	This study conducted in the FDA's Sentinel System is a public health surveillance activity
113	conducted under the authority of the FDA and, accordingly, is not subject to Institutional Review
114	Board oversight. ⁹⁻¹¹ This study followed the Strengthening the Reporting of Observational
115	Studies in Epidemiology (STROBE) reporting guideline.

117 **RESULTS**

118 During the study period (May 2012-December 2020), we identified 7,925,941; 442,189 and 119 16,260 valsartan episodes in US, Canada, and Denmark. The distribution of valsartan use by 120 exposure category during the study period for all three countries is presented in Table 1. 121 Exposure to both recalled-tested and recalled products was extensive in the US and Canada. We 122 identified 3.3 (41.6%) and 2.8 (35.7%) million recalled-tested and recalled valsartan exposure 123 episodes in the US and 51,315 (11.6%) and 291,229 (65.9%) recalled-tested and recalled 124 episodes were identified in the Canadian database. In Denmark, the proportion of recalled valsartan exposure was high; 10,747 (66.1%) recalled episodes were identified. Exposure to non-125 126 recalled generic and non-recalled branded valsartan products was comparable to the exposure to 127 the recalled products, for all three countries. Around 3.3 (41.5%) and 3.2 (40%) million non-128 recalled generic and branded episodes, respectively, were identified in Sentinel, while 35,978 129 (8.1%) and 215,999 (48.8%) episodes for non-recalled generic and branded were identified in the 130 Canadian data. In Denmark, 9,395 (57.8%) and 7,632 (46.9%) non-recalled generic and branded 131 valsartan episodes were identified (Table 1).

132 Trends in valsartan use

The trends in valsartan use, stratified by valsartan impurity status for US, Canada and Denmarkare presented in Figures 1-3.

135 US

136 In the US, between 2012 and 2015, we observed a steady decline in use of valsartan branded

137 episodes, along with a corresponding increase in the share of the generic (recalled-tested,

138 recalled and non-recalled) products (Figure 1). Recalled-tested products had the largest share of

139	the generic valsartan market in 2012; however, between 2014 and 2015, both non-recalled and
140	recalled products equally shared the valsartan market (Figure 1). Between the third calendar
141	quarter (Q3: July-September) of 2016 and Q3-2018, recalled-tested valsartan products had the
142	largest market share of valsartan products, followed by the recalled products. From Q3 to Q4
143	(October-December) 2018, we observed a steep drop (from 46.0% to 13.9%) in the proportion of
144	recalled-tested valsartan products. The decline in use of recalled products started from Q1
145	(January-March) 2019.
146	Canada
147	In Canada, recalled products were the most dispensed valsartan products, followed by non-
148	recalled branded products (Figure 2). Between Q3- and Q4-2018, there was a steep drop in the
149	proportion of recalled products (from 90% in Q2 (April-May) 2018 to 2.6% in Q4-2018); while
150	the trends for non-recalled branded products remained unaffected. Use of recalled-tested and
151	non-recalled generic products was low during the study period.
152	Denmark
153	In Denmark, recalled products were the most dispensed valsartan products (Figure 3). Decline in
154	the use of these products beginning in 2017 coincided with the steady increase in non-recalled
155	branded products. When the recall notice was issued (Q3-2018), there was a steep decline from
156	41% (Q3-2018) to 13% (Q4-2018) in recalled products, whereas the proportion of non-recalled
157	branded products increased from 49% to 56% around the same time.

158 **Duration of valsartan episodes**

159 The duration of valsartan exposure episodes, stratified by valsartan-impurity status for the three160 countries, is presented in Table 2. The mean duration of use of the recalled-tested products was

161	166.9(\pm 223.1) and 145.5(\pm 255.8) days in the US and Canada. The 75 th percentile ranged from
162	60-222 days for US and 139-192 days for Canada. For the recalled products, mean duration of
163	use was 178.3(±249.6), 269.0(±397.3) and 166(±251.0) days for US, Canada, and Denmark. The
164	75 th percentile range was 60-230, 315-407 and 181 days for US, Canada, and Denmark. The
165	mean duration of use for the non-recalled generic products appeared comparable to mean
166	duration for recalled-tested (US, Canada) and recalled products (Denmark). In Canada (319.2
167	(± 489.1)) and Denmark (321.6(± 376.2) days), the mean duration of use of the non-recalled
168	branded products was much longer compared to the duration of use in the US (167.7(\pm 228.0)
169	days).

170 Valsartan switching patterns.

171 In US and Canada, we observed relatively stable switching patterns for both recalled-tested and

recalled products prior to Q2-20718 (Supplemental Figures 1 and 3). In Q2-2018, there was an

173 immediate increase in the switching between valsartan exposure categories and to a non-

174 valsartan ARB. In Denmark, a similar increase in switching was also observed in Q2-2018;

175 however, there was frequent switching from recalled products to non-recalled valsartan products

176 (Supplemental Figure 5). Interestingly, in Q2-2018, there was increased switching from non-

177 recalled valsartan products to a non-valsartan ARB in the US and Canada (Supplemental Figures

178 2 and 4). In Canada, switching from branded valsartan to a non-valsartan ARB increased in Q2-

179 2018 (Supplemental Figure 4), but this trend was not observed in the other countries. In

180 Denmark, switching from the non-recalled generic and branded products to recalled products

181 prior to Q2-2018 was frequent. After Q2-2018, switching rates diminished.

183 **DISCUSSION**

184 Our findings suggest that many patients received valsartan products with nitrosamine impurities, 185 at the time when there was no knowledge of the nitrosamine impurities. In all three countries, 186 recalled-tested and recalled valsartan products had the largest share of the valsartan market. 187 Despite widespread use of the products with nitrosamine impurities, duration of use was 188 typically very short. The mean duration of use was around 4 months in the US and Denmark. In 189 Canada, the mean duration of use was slightly longer, at about 8 months. Further, about 75% of 190 the affected valsartan episodes were not longer than 8 months in US and Denmark and 12 191 months in Canada. This translates to a maximum duration of exposure of 1.5% (12 months out of 192 840 months (70 years)) of the lifetime exposure for most cancer risk assessments. Our study also 193 revealed that despite availability of non-recalled valsartan products, the preference was to switch 194 to non-valsartan ARB after the recall notices were issued in July 2018. 195 Nitrosamines, NDMA and NDEA are classified as probable carcinogens for humans given the limited evidence of carcinogenicity in humans but established evidence in animal studies.⁵ 196 197 NDMA and NDEA are suspected to have both local and systemic carcinogenic potential following activation to diazonium ions (methyldiazonium, ethlydiazonium).¹³ These diazonium 198 199 ions are precursors of reactive electrophilic carbenium ions, which directly react with DNA to 200 form stable adducts (a segment of the DNA bound to a carcinogenic chemical). Adducts that are not removed by the cell can cause mutations that may give rise to cancer.¹⁴ As such it is expected 201 202 that chronic exposure to nitrosamines is necessary for carcinogenesis. With regards to types of 203 cancers, the EMA's ad-hoc expert group on nitrosamine impurities in human medicinal products¹⁵ concluded that the liver may be the most impacted organ due to activation of 204 205 nitrosamines during first pass hepatic metabolism. Activated nitrosamines are very reactive and

are unlikely to be released into the circulation. However, many other sites, including the
gastrointestinal tract, are metabolically competent and can also activate nitrosamines.^{16,17} Based
on the duration of exposure found in our study, a marked increased risk of liver or the
gastrointestinal cancer from the nitrosamine impurity is unlikely. An observational study
conducted to examine risk of these cancers also found no increased risk for cancers with
valsartan products.¹⁸

Our study has several strengths. It is the first observational study to date to characterize the extent of exposure to valsartan products with nitrosamine impurities in three countries. It covers the entire period when the valsartan products with nitrosamine impurities were in circulation, allowing for the complete capture of nitrosamine exposure from valsartan products described within the study databases. The use of dispensing claims data means that patients filled their prescriptions, though the actual ingestion of these products cannot be confirmed.

218 LIMITATIONS

219 Within the recalled-tested products, it was likely that all products lots for the assigned NDC were 220 affected. However, for the recalled products, only selected lots are indicated on the recalled list 221 were affected by the contamination. For recalled products, our exposure algorithm was unable to 222 identify specific affected lots. Thus, the proportion of recalled valsartan episodes may be 223 overestimated. We were also unable to identify a date when all valsartan products with 224 nitrosamine impurities were no longer on the market. To estimate exposure, we assumed that 225 valsartan products with nitrosamine impurities were no longer on market by December 2018, but 226 we acknowledge that this may not have been the case across the board. Another limitation relates 227 to potential additional contamination exposure from switching to non-valsartan ARBs that were 228 affected prior to issuance of the recall notices. It is possible that prior to the recall dates valsartan

users switched to other affected ARBs and could have had additional exposure to nitrosamine impurities. However, we were unable to evaluate this possibility as the date of first introduction of the nitrosamine impurities for the other ARBs was not well characterized at the time of the analysis. Lastly, we acknowledge that there could be other sources of nitrosamine exposure from water and food, which may also affect cancer risk, and these were not considered in this study.

234 CONCLUSION

Between 2012 and 2018, recalled generic valsartan products had the largest share of the valsartan

236 market in the US, Canada, and Denmark. Despite widespread use, the duration of use of recalled

237 products was relatively short and likely does not pose an elevated risk of nitrosamine-induced

238 cancer. However, since products with nitrosamine impurity could have been on the market over a

six-year period, patients potentially exposed to these products for longer duration could have a

240 different risk of cancer.

241 Acknowledgments, Sources of Funding, & Disclosures

a) Acknowledgements

243 Many thanks are due to those who participated in this project:

244 The Canadian Network for Observational Drug Effect Studies (CNODES), a collaborating center

of the Drug Safety and Effectiveness Network (DSEN). This study was made possible through

246 data-sharing agreements between the CNODES member research centers and the respective

247 provincial governments of Manitoba, Nova Scotia, Ontario, and Saskatchewan.

248 U.S. Data Partners who provided data used in the analysis: CVS Health (Aetna), Bell, PA;

249 Carelon Research/Elevance Health, Wilmington, DE; Duke University School of Medicine,

250 Department of Population Health Sciences, Durham, NC, through the Centers for Medicare and

251	Medicaid Services which provided data; Humana Healthcare Research Inc., Louisville, KY;
252	Northern California, Division of Research, Oakland, CA; OptumInsight Life Sciences Inc.,
253	Boston, MA; Vanderbilt University Medical Center, Department of Health Policy, Nashville,
254	TN, through the TennCare Division of the Tennessee Department of Finance & Administration
255	which provided data.

b) Sources of Funding

257 The Canadian Network for Observational Drug Effect Studies (CNODES) is a core network

258 partner of CoLab and funded by Canadian Agency for Drugs and Technologies in Health,

259 CADTH (Grant #C222 360). At the time of this study CNODES was a collaborating center of

260 the Drug Safety and Effectiveness Network (DSEN) and funded by the Canadian Institutes of

261 Health Research (CIHR; Grant # DSE-146021). This study was made possible through data

sharing agreements between the participating CNODES member research centers and the

263 respective provincial governments of Manitoba, Nova Scotia, Ontario, and Saskatchewan. This

264 project was supported by Task Order 75F40119F19002 under Master Agreement

265 75F40119D10037 from the U.S. Food and Drug Administration (FDA).

266 c) Disclosures

The FDA approved the study protocol including statistical analysis plan, and reviewed and approved this manuscript. Authors who are employees or contractors of the U.S. Food and Drug Administration, played a role in the design, results interpretation and in the preparation and decision to submit the manuscript for publication; however, other officials at the U.S. Food and Drug Administration, had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The Danish regulatory

274	authority and CADTH and the Canadian Institutes of Health Research had no role in the design
275	and conduct of the study; collection, management, analysis, and interpretation of the data; and
276	preparation, review, or approval of the manuscript; and decision to submit the manuscript for
277	publication.
278	Disclaimers: The opinions, results, and conclusions are those of the authors; no endorsement by
279	the provincial governments, data stewards, Health Canada, CADTH or CIHR is intended or
280	should be inferred. The views expressed are the authors' and not necessarily those of the U.S.
281	Food and Drug Administration, or the U.S. Department of Health and Human Services.
282	

284 **REFERENCES**

285 1. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. 2018. Accessed May 26, 2022. https://www.fda.gov/news-events/press-286 287 announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-288 following-detection-impurity 289 EMA reviewing medicines containing valsartan from Zhejiang Huahai following 2. 290 detection of an impurity: some valsartan medicines being recalled across the EU. 2018. Accessed 291 May 26, 2022. https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-292 valsartan-zhejiang-huahai-following-detection-impurity-some 293 3. Several drugs containing valsartan being recalled due to contamination with a potential 294 carcinogen. 2018. Accessed May 26, 2022. https://recalls-rappels.canada.ca/en/alertrecall/several-drugs-containing-valsartan-being-recalled-due-contamination-potential 295 296 Blood pressure and heart medication recalled from Pharmacie. 2018. Accessed May 26, 4. 297 2022. https://www.gov.uk/government/news/blood-pressure-and-heart-medication-recalled-298 from-pharmacies International Agency for Research on Cancer (IARC). IARC monographs on the 299 5. 300 evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating 301 of IARC Monographs. Vol. 1-42. 1987. 302 Eworuke E, Shinde M, Hou L, Paterson MJ, Jensen PB, Maro JC, Rai A, Scarnecchia D, 6. 303 Pennap D, Woronow D, Ghosh RE, Welburn S, Pottegard A, Platt RW, Lee H, Bradley MC. 304 Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the 305 nitrosamine recalls: a descriptive cohort study. BMJ Open. 2023 Apr 17;13(4):e070985. doi: 306 10.1136/bmjopen-2022-070985. 307 US Food and Drug Administration. Laboratory analysis of valsartan products. Accessed 7. 308 May 26, 2022, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/search-list-recalledangiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and 309 310 Government of Canada. Impurities found in certain angiotensin II receptor blocker 8. 311 (ARB) products, also known as sartans. Accessed 12/20/2022, 2022. 312 https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-313 enforcement/information-health-product/drugs/angiotensin-receptor-blocker.html 314 Basic HHS Policy for Protection of Human Research Subjects, Title 45 82 FR 7259, 7273 9. 315 1-23 (2017). https://www.fda.gov/drugs/drug-safety-and-availability/information-about-316 nitrosamine-impurities-medications 317 Federal Policy for the Protection of Human Subjects. In: Office for Human Research 10. 318 Protections (OHRP) DoHaHS, editor. 82 FR 71492017. p. 126. 319 Rosati K JN, Soliz M, Evans BJ. . Sentinel Initiative Principles and Policies: HIPAA and 11. Common Rule Compliance in the Sentinel Initiative. 2018. 320 321 12. Sentinel Operations Center. Common data model. 322 https://dev.sentinelsystem.org/projects/SCDM/repos/sentinel common data model/browse 323 Peto R, Gray R, Brantom P, Grasso P. Nitrosamine carcinogenesis in 5120 rodents: 13. 324 chronic administration of sixteen different concentrations of NDEA, NDMA, NPYR and NPIP in 325 the water of 4440 inbred rats, with parallel studies on NDEA alone of the effect of age of starting 326 (3, 6 or 20 weeks) and of species (rats, mice or hamsters). IARC Sci Publ. 1984;(57):627-65.

327 14. Portfolio N. DNA Adducts. Accessed 12/15/2022, https://www.nature.com/subjects/dna 328 adducts

329 15. European Medicines Agency. Pharmacovigilance Risk Assessment Committee: Minutes330 of meeting on 10-13 February 2020. 2020:82.

Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence,
formation, mechanisms and carcinogenic potential. *Mutation Research/Genetic Toxicology*.
1991/03/01/ 1991;259(3):277-289. doi:https://doi.org/10.1016/0165-1218(91)90123-4

- 334 17. Bartsch H, O'Neill IK. Ninth International Meeting on N-Nitroso Compounds:
- Exposures, Mechanisms, and Relevance to Human Cancer1. *Cancer Research*.

336 1988;48(16):4711-4714.

337 18. Pottegård A, Christensen Rd, Houji A, et al. Primary non-adherence in general practice: a

Danish register study. *European Journal of Clinical Pharmacology*. 2014/06/01 2014;70(6):757 763. doi:10.1007/s00228-014-1677-y

340




Figure 1. Trends in valsartan utilization stratified by nitrosamine impurity status in the US. The solid lines represent valsartan use while the products with nitrosamine impurities were on the market; the dotted lines represent use when the products with nitrosamine impurities were assumed to be removed from the market (Jan 2019- Dec 2020). For recalled products, use after 2019 reflects production without nitrosamine impurities.




Figure 2. Trends in valsartan utilization stratified by nitrosamine impurity status in Canada. The solid lines represent valsartan use while the products with nitrosamine impurities were on the market; the dotted lines represent use when the products with nitrosamine impurities were assumed to be removed from the market (Jan 2019- Dec 2020). For recalled products, use after 2019 reflects production without nitrosamine impurities.




Figure 3 Trends in valsartan utilization stratified by nitrosamine impurity status in Denmark. The solid lines represent valsartan use while the products with nitrosamine impurities were on the market; the dotted lines represent use when the products with nitrosamine impurities were assumed to be removed from the market (Jan 2019- Dec 2020).

362 Table 1. Characteristics of valsartan users, stratified by valsartan nitrosamine-impurity status for US, Canada, and Denmark between

363 May 1, 2012, through December 31, 2020,

	US	S (N=7,925,9	41 total episod	des)	Cana	da (N=442,1	89 total epis	Denmark* (N=16,260 total episodes)				
	Non- Non-						Non- Non-			Non-		
	Recalled-		recalled	recalled	Recalled		recalled	recalled		recalled	Non-recalled	
	tested	Recalled	Generic	Branded	-tested	Recalled	Generic	Branded	Recalled	Generic	Branded	
	products	products	products	products	products	products	products	products	products	products	products (N,	
Characteristics	(N, %)	(N, %)	(N, %)	(N, %)	(N, %)	(N, %)	(N, %)	(N, %)	(N, %)	(N, %)	%)	
Number of	3,299,942	2,826,914	3,285,556	3,167,728	51,315	291,229	35,973	215,999	10,747	9,395	7,632	
episodes	(41.6)	(35.7)	(41.5)	(40.0)	(11.6)	(65.9)	(8.1)	(48.8)	(66.1)	(57.8)	(46.9)	
Number of												
unique patients	2,042,708	1,683,995	1,972,104	1,884,770	34,893	156,933	26,105	114,546	4,020	3,361	4,707	
Demographics												
Age [†] , %												
18-44	3.7	3.9	3.7	4.5	2.1	2.7	2.2	2.2	3.4	3.2	3.0	
45-64	25.0	25.7	24.1	26.0	16.9	17.7	15.2	17.1	38.1	35.4	31.2	
>65	71.3	70.4	72.2	69.5	81.0	79.6	82.6	80.6	58.5	61.5	65.7	
Sex, %												
Female	57.1	56.8	56.9	54.2	56.2	57.2	57.4	51.3	51.8	52.0	35.6	
Male	42.9	43.2	43.1	45.8	43.8	42.8	42.6	48.7	48.2	48.0	64.4	

*In Denmark, due to the inability to access testing data, the recalled products were not further categorized into recalled-tested and recalled
 products.

366 [†]Age at index date (first valsartan dispensing)

367

368

Table 2. Summary statistics for the duration of valsartan episodes between May 1, 2012, and December 31, 2018*, by valsartan

371 nitrosamine-impurity status

		Ţ	JS			Canada							Denmark					
Valsartan	Total episodes	Mea n (day	St. Dev (day	Medi an (days	25th Percen tile	75th Percen	Total episo des	Mea n (day	St. Dev (day	Medi an (days	25th Percen tile	75th Percen tile	Total episo des	Mea n (day	St. Dev (day	Medi an (days	25th Percen tile	75th Percen tile
Category Recalled-tested	(N) 2,516,12	s) 166. 9	s) 223. 1) 29- 93	(days) 2-32	tile 60-222	(N) 36786	s) 145. 4	s) 255. 8) 48-69	(days) 4-9	(days) 139- 192	(N) 10,55	s) 166.	s) 251.)	(days)	(days)
Recalled	2,265,23 8	178. 3	249. 6	28- 95	2-35	60-230	26735 5	269. 0	397. 3	104- 121	22-50	315- 407	1	2	0	99	30	181
Non-recalled generic	2,020,03 2	164. 7	231. 4	20- 93	1-32	60-213	23106	146. 7	230. 9	61- 85.5	5-11	174- 255.5	8108	136. 8	194. 0	90	28	142
Non-recalled branded	2,639,38 0	167. 7	228. 0	60- 100	5-53	96-219	15786 3	319. 2	489. 1	98- 120	16-25	356- 400	4708	321. 6	376. 2	154	58	497.5

372 Mean duration in US and Canada databases is an average of the episode duration across all data partners. Median, 25th and 75th

373 percentiles are the lowest and highest value reported across the data partners.

374

375 * period valsartan products with NDMA/NDEA impurity were assumed to have been available